OBJECTIVES: Differentiating true progression or recurrence (TP/TR) from therapy-related changes (TRC) is complex in brain tumours. Amide proton transfer-weighted (APT) imaging is a chemical exchange saturation transfer (CEST) MRI technique that may improve diagnostic accuracy during radiological follow-up. This systematic review and meta-analysis elucidated the level of evidence and details of state-of-the-art imaging for APT-CEST in glioma and brain metastasis surveillance. METHODS: PubMed, EMBASE, Web of Science, and Cochrane Library were systematically searched for original articles about glioma and metastasis patients who received APT-CEST imaging for suspected TP/TR within 2 years after (chemo)radiotherapy completion. Modified Quality Assessment of Diagnostic Accuracy Studies-2 criteria were applied. A meta-analysis was performed to pool results and to compare subgroups. RESULTS: Fifteen studies were included for a narrative synthesis, twelve of which (500 patients) were deemed sufficiently homogeneous for a meta-analysis. Magnetisation transfer ratio asymmetry performed well in gliomas (sensitivity 0.88 [0.82-0.92], specificity 0.84 [0.72-0.91]) but not in metastases (sensitivity 0.64 [0.38-0.84], specificity 0.56 [0.33-0.77]). APT-CEST combined with conventional/advanced MRI rendered 0.92 [0.86-0.96] and 0.88 [0.72-0.95] in gliomas. Tumour type, TR prevalence, sex, and acquisition protocol were sources of significant inter-study heterogeneity in sensitivity (I2 = 62.25%; p < 0.01) and specificity (I2 = 66.31%; p < 0.001). CONCLUSION: A growing body of literature suggests that APT-CEST is a promising technique for improving the discrimination of TP/TR from TRC in gliomas, with limited data on metastases. CLINICAL RELEVANCE STATEMENT: This meta-analysis identified a utility for APT-CEST imaging regarding the non-invasive discrimination of brain tumour progression from therapy-related changes, providing a critical evaluation of sequence parameters and cut-off values, which can be used to improve response assessment and patient outcome. KEY POINTS: Therapy-related changes mimicking progression complicate brain tumour treatment. Amide proton imaging improves the non-invasive discrimination of glioma progression from therapy-related changes. Magnetisation transfer ratio asymmetry measurement seems not to have added value in brain metastases.

Amsterdam Neuroscience Brain Imaging De Boelelaan 1117 1081HV Amsterdam Netherlands

Cancer Center Amsterdam Imaging and Biomarkers De Boelelaan 1117 1081HV Amsterdam Netherlands

Charles University The 2nd Faculty of Medicine Department of Pathophysiology Prague Czech Republic

Department of Radiology and Nuclear Medicine Amsterdam University Medical Center De Boelelaan 1117 1081HV Amsterdam Netherlands

Zobrazit více v PubMed

Thust SC, van den Bent MJ, Smits M (2018) Pseudoprogression of brain tumors. J Magn Reson Imaging 48:571–589 PubMed PMC

Zikou A, Sioka C, Alexiou GA, Fotopoulos A, Voulgaris S, Argyropoulou MI (2018) Radiation necrosis, pseudoprogression, pseudoresponse, and tumor recurrence: imaging challenges for the evaluation of treated gliomas. Contrast Media Mol Imaging 2018:6828396 PubMed PMC

Qin D, Yang G, Jing H, Tan Y, Zhao B, Zhang H (2022) Tumor progression and treatment-related changes: radiological diagnosis challenges for the evaluation of post treated glioma. Cancers (Basel) 14:3771 PubMed PMC

Yun TJ, Park CK, Kim TM et al (2015) Glioblastoma treated with concurrent radiation therapy and temozolomide chemotherapy: differentiation of true progression from pseudoprogression with quantitative dynamic contrast-enhanced MR imaging. Radiology 274:830–840 PubMed

Lacerda S, Barisano G, Shiroishi MS, Law M (2023) Clinical applications of dynamic contrast-enhanced (DCE) permeability imaging. In: Faro SH, Mohamed FB (eds) Functional neuroradiology: principles and clinical applications. Springer, Cham, 175–200

Ahn SS, Cha S (2021) Pre- and post-treatment imaging of primary central nervous system tumors in the molecular and genetic era. Korean J Radiol 22:1858–1874 PubMed PMC

Quan G, Zhang K, Liu Y et al (2021) Role of dynamic susceptibility contrast perfusion MRI in glioma progression evaluation. J Oncol 2021:1696387 PubMed PMC

Zhou J, Lal B, Wilson DA, Laterra J, van Zijl PCM (2003) Amide proton transfer (APT) contrast for imaging of brain tumors. Magn Reson Med 50:1120–1126 PubMed

Zhou J, Tryggestad E, Wen Z et al (2011) Differentiation between glioma and radiation necrosis using molecular magnetic resonance imaging of endogenous proteins and peptides. Nat Med 17:130–134 PubMed PMC

Zhou J, Zaiss M, Knutsson L et al (2022) Review and consensus recommendations on clinical APT-weighted imaging approaches at 3T: application to brain tumors. Magn Reson Med 88:546–574 PubMed PMC

Booth TC, Wiegers EC, Warnert EAH et al (2021) High-grade glioma treatment response monitoring biomarkers: a position statement on the evidence supporting the use of advanced MRI techniques in the clinic, and the latest bench-to-bedside developments. Part 2: Spectroscopy, chemical exchange saturation, multiparametric imaging, and radiomics. Front Oncol 11:811425 PubMed PMC

Chen K, Jiang XW, Deng LJ, She HL (2022) Differentiation between glioma recurrence and treatment effects using amide proton transfer imaging: a mini-Bayesian bivariate meta-analysis. Front Oncol 12:852076 PubMed PMC

Verma N, Cowperthwaite MC, Burnett MG, Markey MK (2013) Differentiating tumor recurrence from treatment necrosis: a review of neuro-oncologic imaging strategies. Neuro Oncol 15:515–534 PubMed PMC

Okuchi S, Hammam A, Golay X, Kim M, Thust S (2020) Endogenous chemical exchange saturation transfer MRI for the diagnosis and therapy response assessment of brain tumors: a systematic review. Radiol Imaging Cancer 2:e190036 PubMed PMC

McInnes MDF, Moher D, Thombs BD, McGrath TA, Bossuyt PM (2018) Preferred reporting items for a systematic review and meta-analysis of diagnostic test accuracy studies: the PRISMA-DTA statement. JAMA 319:388–396 PubMed

Whiting PF, Rutjes AW, Westwood ME et al (2011) QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 155:529–536 PubMed

Paprottka KJ, Kleiner S, Preibisch C et al (2021) Fully automated analysis combining [18F]-FET-PET and multiparametric MRI including DSC perfusion and APTw imaging: a promising tool for objective evaluation of glioma progression. Eur J Nucl Med Mol Imaging 48:4445–4455 PubMed PMC

Guo PF, Unberath M, Heo HY et al (2022) Learning-based analysis of amide proton transfer-weighted MRI to identify true progression in glioma patients. Neuroimage Clin 35:9 PubMed PMC

Hou HM, Diao YZ, Yu JC et al (2023) Differentiation of true progression from treatment response in high-grade glioma treated with chemoradiation: a comparison study of 3D-APTW and 3D-PcASL imaging and DWI. NMR Biomed 36:9 PubMed

Huang QQ, Wu JP, Le NT et al (2023) CEST2022: amide proton transfer-weighted MRI improves the diagnostic performance of multiparametric non-contrast-enhanced MRI techniques in patients with post-treatment high-grade gliomas. Magn Reson Imaging 102:222–228 PubMed PMC

Jiang SS, Guo PF, Heo HY et al (2023) Radiomics analysis of amide proton transfer-weighted and structural MR images for treatment response assessment in malignant gliomas. NMR Biomed 36:11 PubMed PMC

Liu J, Li C, Chen YS et al (2020) Diagnostic performance of multiparametric MRI in the evaluation of treatment response in glioma patients at 3T. J Magn Reson Imaging 51:1154–1161 PubMed

Park KJ, Kim HS, Park JE, Shim WH, Kim SJ, Smith SA (2016) Added value of amide proton transfer imaging to conventional and perfusion MR imaging for evaluating the treatment response of newly diagnosed glioblastoma. Eur Radiol 26:4390–4403 PubMed

Park YW, Ahn SS, Kim EH et al (2021) Differentiation of recurrent diffuse glioma from treatment-induced change using amide proton transfer imaging: incremental value to diffusion and perfusion parameters. Neuroradiology 63:363–372 PubMed

Jiang SS, Eberhart CG, Lim M et al (2019) Identifying recurrent malignant glioma after treatment using amide proton transfer-weighted MR imaging: a validation study with image-guided stereotactic biopsy. Clin Cancer Res 25:552–561 PubMed PMC

Kroh F, Doeberitz NV, Breitling J et al (2023) Semi-solid MT and APTw CEST-MRI predict clinical outcome of patients with glioma early after radiotherapy. Magn Reson Med 90:1569–1581 PubMed

Ma B, Blakeley JO, Hong X et al (2016) Applying amide proton transfer-weighted MRI to distinguish pseudoprogression from true progression in malignant gliomas. J Magn Reson Imaging 44:456–462 PubMed PMC

Mehrabian H, Chan RW, Sahgal A et al (2023) Chemical exchange saturation transfer MRI for differentiating radiation necrosis from tumor progression in brain metastasis-application in a clinical setting. J Magn Reson Imaging 57:1713–1725 PubMed

Mehrabian H, Desmond KL, Soliman H, Sahgal A, Stanisz GJ (2017) Differentiation between radiation necrosis and tumor progression using chemical exchange saturation transfer. Clin Cancer Res 23:3667–3675 PubMed

Park JE, Kim HS, Park KJ, Kim SJ, Kim JH, Smith SA (2016) Pre-and posttreatment glioma: comparison of amide proton transfer imaging with MR spectroscopy for biomarkers of tumor proliferation. Radiology 278:514–523 PubMed

Park JE, Lee JY, Kim HS et al (2018) Amide proton transfer imaging seems to provide higher diagnostic performance in post-treatment high-grade gliomas than methionine positron emission tomography. Eur Radiol 28:3285–3295 PubMed

Louis DN, Perry A, Wesseling P et al (2021) The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol 23:1231–1251 PubMed PMC

Mayo ZS, Halima A, Broughman JR et al (2023) Radiation necrosis or tumor progression? A review of the radiographic modalities used in the diagnosis of cerebral radiation necrosis. J Neurooncol 161:23–31 PubMed

Desmond KL, Mehrabian H, Chavez S et al (2017) Chemical exchange saturation transfer for predicting response to stereotactic radiosurgery in human brain metastasis. Magn Reson Med 78:1110–1120 PubMed

Lingl JP, Wunderlich A, Goerke S et al (2022) The value of APTw CEST MRI in routine clinical assessment of human brain tumor patients at 3T. Diagnostics 12:490 PubMed PMC

Brandes AA, Franceschi E, Tosoni A et al (2008) MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol 26:2192–2197 PubMed

Suh CH, Park JE, Jung SC, Choi CG, Kim SJ, Kim HS (2019) Amide proton transfer-weighted MRI in distinguishing high- and low-grade gliomas: a systematic review and meta-analysis. Neuroradiology 61:525–534 PubMed

Young JS, Al-Adli N, Scotford K, Cha S, Berger MS (2023) Pseudoprogression versus true progression in glioblastoma: what neurosurgeons need to know. J Neurosurg 139:748–759 PubMed PMC

Deeks JJ, Macaskill P, Irwig L (2005) The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. J Clin Epidemiol 58:882–893 PubMed